Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Research & Development (2016 - 2025)

United Therapeutics (UTHR) has disclosed Research & Development for 17 consecutive years, with $139.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 4.26% to $139.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $550.0 million through Dec 2025, up 14.35% year-over-year, with the annual reading at $550.0 million for FY2025, 14.35% up from the prior year.
  • Research & Development hit $139.5 million in Q4 2025 for United Therapeutics, up from $127.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $303.7 million in Q1 2021 to a low of $66.1 million in Q3 2022.
  • Historically, Research & Development has averaged $115.1 million across 5 years, with a median of $98.7 million in 2022.
  • Biggest five-year swings in Research & Development: soared 314.89% in 2021 and later tumbled 77.28% in 2022.
  • Year by year, Research & Development stood at $82.9 million in 2021, then rose by 13.27% to $93.9 million in 2022, then soared by 61.24% to $151.4 million in 2023, then fell by 11.62% to $133.8 million in 2024, then grew by 4.26% to $139.5 million in 2025.
  • Business Quant data shows Research & Development for UTHR at $139.5 million in Q4 2025, $127.5 million in Q3 2025, and $134.0 million in Q2 2025.